Annual CFO
-$22.43 M
+$6.04 M+21.22%
December 31, 2023
Summary
- As of February 7, 2025, CDTX annual cash flow from operations is -$22.43 million, with the most recent change of +$6.04 million (+21.22%) on December 31, 2023.
- During the last 3 years, CDTX annual CFO has risen by +$31.98 million (+58.77%).
- CDTX annual CFO is now -2040.46% below its all-time high of -$1.05 million, reached on December 31, 2013.
Performance
CDTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$36.70 M
+$67.08 M+64.64%
September 30, 2024
Summary
- As of February 7, 2025, CDTX quarterly cash flow from operations is -$36.70 million, with the most recent change of +$67.08 million (+64.64%) on September 30, 2024.
- Over the past year, CDTX quarterly CFO has dropped by -$23.97 million (-188.44%).
- CDTX quarterly CFO is now -231.18% below its all-time high of $27.97 million, reached on September 30, 2022.
Performance
CDTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$159.84 M
-$35.06 M-28.10%
September 30, 2024
Summary
- As of February 7, 2025, CDTX TTM cash flow from operations is -$159.84 million, with the most recent change of -$35.06 million (-28.10%) on September 30, 2024.
- Over the past year, CDTX TTM CFO has dropped by -$137.41 million (-612.56%).
- CDTX TTM CFO is now -38885.61% below its all-time high of -$410.00 thousand, reached on March 31, 2014.
Performance
CDTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
CDTX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +21.2% | -188.4% | -612.6% |
| 3 y3 years | +58.8% | -236.7% | -914.0% |
| 5 y5 years | +60.4% | -236.7% | -914.0% |
CDTX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +21.2% | -231.2% | +64.6% | <-9999.0% | at low |
| 5 y | 5-year | at high | +58.8% | -231.2% | +64.6% | <-9999.0% | at low |
| alltime | all time | -2040.5% | +60.4% | -231.2% | +64.6% | <-9999.0% | at low |
Cidara Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$36.70 M(-64.6%) | -$159.84 M(+28.1%) |
| Jun 2024 | - | -$103.78 M(+1462.0%) | -$124.78 M(+586.4%) |
| Mar 2024 | - | -$6.64 M(-47.8%) | -$18.18 M(-19.0%) |
| Dec 2023 | -$22.43 M(-21.2%) | -$12.72 M(+678.6%) | -$22.43 M(-27.0%) |
| Sep 2023 | - | -$1.63 M(-157.9%) | -$30.71 M(+2679.4%) |
| Jun 2023 | - | $2.82 M(-125.9%) | -$1.10 M(-93.0%) |
| Mar 2023 | - | -$10.90 M(-48.1%) | -$15.76 M(-44.6%) |
| Dec 2022 | -$28.47 M(+12.8%) | -$21.00 M(-175.1%) | -$28.47 M(+27.2%) |
| Sep 2022 | - | $27.97 M(-336.3%) | -$22.38 M(-64.1%) |
| Jun 2022 | - | -$11.84 M(-49.9%) | -$62.32 M(+32.5%) |
| Mar 2022 | - | -$23.61 M(+58.4%) | -$47.05 M(+86.5%) |
| Dec 2021 | -$25.23 M(-53.6%) | -$14.91 M(+24.5%) | -$25.23 M(+17.6%) |
| Sep 2021 | - | -$11.97 M(-448.0%) | -$21.45 M(-9.0%) |
| Jun 2021 | - | $3.44 M(-291.9%) | -$23.56 M(-42.6%) |
| Mar 2021 | - | -$1.79 M(-83.9%) | -$41.08 M(-24.5%) |
| Dec 2020 | -$54.41 M(+90.7%) | -$11.13 M(-21.0%) | -$54.41 M(-7.0%) |
| Sep 2020 | - | -$14.08 M(+0.1%) | -$58.48 M(+110.5%) |
| Jun 2020 | - | -$14.07 M(-7.0%) | -$27.78 M(+4.8%) |
| Mar 2020 | - | -$15.13 M(-0.5%) | -$26.51 M(-7.1%) |
| Dec 2019 | -$28.53 M | -$15.20 M(-191.4%) | -$28.53 M(+5.7%) |
| Sep 2019 | - | $16.62 M(-229.8%) | -$27.00 M(-52.1%) |
| Jun 2019 | - | -$12.81 M(-25.3%) | -$56.40 M(-4.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$17.15 M(+25.5%) | -$59.13 M(+4.3%) |
| Dec 2018 | -$56.70 M(+13.6%) | -$13.67 M(+6.9%) | -$56.70 M(+7.9%) |
| Sep 2018 | - | -$12.78 M(-17.7%) | -$52.53 M(-2.0%) |
| Jun 2018 | - | -$15.53 M(+5.5%) | -$53.61 M(+7.0%) |
| Mar 2018 | - | -$14.72 M(+55.1%) | -$50.11 M(+0.4%) |
| Dec 2017 | -$49.91 M(+25.5%) | -$9.49 M(-31.6%) | -$49.91 M(-4.3%) |
| Sep 2017 | - | -$13.87 M(+15.3%) | -$52.14 M(+13.4%) |
| Jun 2017 | - | -$12.03 M(-17.1%) | -$45.96 M(+5.9%) |
| Mar 2017 | - | -$14.52 M(+23.8%) | -$43.40 M(+9.1%) |
| Dec 2016 | -$39.77 M(+53.2%) | -$11.73 M(+52.5%) | -$39.77 M(+14.3%) |
| Sep 2016 | - | -$7.69 M(-18.8%) | -$34.78 M(+1.1%) |
| Jun 2016 | - | -$9.47 M(-13.0%) | -$34.40 M(+11.7%) |
| Mar 2016 | - | -$10.89 M(+61.6%) | -$30.79 M(+18.6%) |
| Dec 2015 | -$25.96 M(+236.7%) | -$6.74 M(-7.7%) | -$25.96 M(+15.9%) |
| Sep 2015 | - | -$7.30 M(+24.5%) | -$22.39 M(+22.3%) |
| Jun 2015 | - | -$5.87 M(-3.1%) | -$18.31 M(+37.2%) |
| Mar 2015 | - | -$6.05 M(+90.8%) | -$13.35 M(+73.2%) |
| Dec 2014 | -$7.71 M(+635.7%) | -$3.17 M(-1.6%) | -$7.71 M(+69.9%) |
| Sep 2014 | - | -$3.22 M(+256.6%) | -$4.54 M(+245.4%) |
| Jun 2014 | - | -$904.00 K(+120.5%) | -$1.31 M(+220.5%) |
| Mar 2014 | - | -$410.00 K | -$410.00 K |
| Dec 2013 | -$1.05 M | - | - |
FAQ
- What is Cidara Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Cidara Therapeutics?
- What is Cidara Therapeutics annual CFO year-on-year change?
- What is Cidara Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Cidara Therapeutics?
- What is Cidara Therapeutics quarterly CFO year-on-year change?
- What is Cidara Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Cidara Therapeutics?
- What is Cidara Therapeutics TTM CFO year-on-year change?
What is Cidara Therapeutics annual cash flow from operations?
The current annual CFO of CDTX is -$22.43 M
What is the all time high annual CFO for Cidara Therapeutics?
Cidara Therapeutics all-time high annual cash flow from operations is -$1.05 M
What is Cidara Therapeutics annual CFO year-on-year change?
Over the past year, CDTX annual cash flow from operations has changed by +$6.04 M (+21.22%)
What is Cidara Therapeutics quarterly cash flow from operations?
The current quarterly CFO of CDTX is -$36.70 M
What is the all time high quarterly CFO for Cidara Therapeutics?
Cidara Therapeutics all-time high quarterly cash flow from operations is $27.97 M
What is Cidara Therapeutics quarterly CFO year-on-year change?
Over the past year, CDTX quarterly cash flow from operations has changed by -$23.97 M (-188.44%)
What is Cidara Therapeutics TTM cash flow from operations?
The current TTM CFO of CDTX is -$159.84 M
What is the all time high TTM CFO for Cidara Therapeutics?
Cidara Therapeutics all-time high TTM cash flow from operations is -$410.00 K
What is Cidara Therapeutics TTM CFO year-on-year change?
Over the past year, CDTX TTM cash flow from operations has changed by -$137.41 M (-612.56%)